share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K:重大事件
美股SEC公告 ·  04/25 08:35

Moomoo AI 已提取核心訊息

On April 24, 2024, Mangoceuticals, Inc., a Texas-based corporation, completed a significant transaction by entering into a Patent Purchase Agreement with Intramont Technologies, Inc. The agreement involved Mangoceuticals' acquisition of patents and patent applications related to the prevention of infections, including the common cold, respiratory diseases, and HPV, for a total consideration of $20 million. The payment was structured as $19.6 million in newly designated 6% Series C Convertible Preferred Stock and $400,000 in cash, to be paid in installments by November 30, 2024. The transaction closed on the same day as the agreement, with the issuance of the Series C Shares. Mangoceuticals plans to leverage the acquired patents through its subsidiary, MangoRx IP Holdings, LLC, by developing products such as an oral dissolvable tablet, lozenge, toothpaste...Show More
On April 24, 2024, Mangoceuticals, Inc., a Texas-based corporation, completed a significant transaction by entering into a Patent Purchase Agreement with Intramont Technologies, Inc. The agreement involved Mangoceuticals' acquisition of patents and patent applications related to the prevention of infections, including the common cold, respiratory diseases, and HPV, for a total consideration of $20 million. The payment was structured as $19.6 million in newly designated 6% Series C Convertible Preferred Stock and $400,000 in cash, to be paid in installments by November 30, 2024. The transaction closed on the same day as the agreement, with the issuance of the Series C Shares. Mangoceuticals plans to leverage the acquired patents through its subsidiary, MangoRx IP Holdings, LLC, by developing products such as an oral dissolvable tablet, lozenge, toothpaste, and mouthwash. The company also granted Intramont a co-exclusive license to use the patents and a right of first refusal on any future sale of the patents until April 24, 2027. This strategic move aims to expand Mangoceuticals' product portfolio into the non-prescription preventive care market and is expected to contribute to the company's compliance with Nasdaq's minimum stockholders' equity requirement.
2024年4月24日,總部位於德克薩斯州的公司Mangoceuticals, Inc. 通過與Intramont Technologies, Inc.簽訂了專利購買協議,完成了一項重大交易。該協議涉及Mangoceuticals收購與預防感染(包括普通感冒、呼吸系統疾病和HPV)相關的專利和專利申請,總對價爲2000萬美元。這筆款項的結構爲1,960萬美元新指定的6%C系列可轉換優先股和40萬美元的現金,將在2024年11月30日之前分期支付。該交易在協議簽署的同一天完成,發行了C系列股票。Mangoceuticals計劃通過其子公司MangorX IP Holdings, LLC利用獲得的專...展開全部
2024年4月24日,總部位於德克薩斯州的公司Mangoceuticals, Inc. 通過與Intramont Technologies, Inc.簽訂了專利購買協議,完成了一項重大交易。該協議涉及Mangoceuticals收購與預防感染(包括普通感冒、呼吸系統疾病和HPV)相關的專利和專利申請,總對價爲2000萬美元。這筆款項的結構爲1,960萬美元新指定的6%C系列可轉換優先股和40萬美元的現金,將在2024年11月30日之前分期支付。該交易在協議簽署的同一天完成,發行了C系列股票。Mangoceuticals計劃通過其子公司MangorX IP Holdings, LLC利用獲得的專利,開發口服可溶性片劑、潤喉糖、牙膏和漱口水等產品。該公司還授予Intramont在2027年4月24日之前使用這些專利的共同獨家許可,以及未來出售這些專利的優先拒絕權。這一戰略舉措旨在將Mangoceuticals的產品組合擴展到非處方預防保健市場,預計將有助於該公司遵守納斯達克的最低股東權益要求。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息